Carolyn S. Calfee

Carolyn S. Calfee

Auto-generated profile, based on publicly available information

Carolyn S. Calfee

UCSF, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
CCCarolyn S Calfee
Carolyn S Calfee
KDKevin Delucchi
Kevin Delucchi
PPPolly E Parsons
Polly E Parsons
BTB Taylor Thompson
B Taylor Thompson
LWLorraine B Ware
Lorraine B Ware
MMMichael A Matthay
Michael A Matthay

1 February 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KFKatie R. Famous
Katie R. Famous
KDKevin Delucchi
Kevin Delucchi
LWLorraine B. Ware
Lorraine B. Ware
KKKirsten N. Kangelaris
Kirsten N. Kangelaris
KLKathleen D. Liu
Kathleen D. Liu
CCCarolyn S. Calfee
Carolyn S. Calfee
Rationale: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes in two separate randomized controlled trials with differential response to positive end-expiratory pressure. Objectives: To identify these subphenotypes in a third ARDS cohort, to test whether subphenotypes respond differently to fluid management strategy, and to develop a practical model for subphenotype identification. Methods: We used latent class analysis of baseline clinical and plasma biomarker data to identify subphenotypes in FACTT (Fluid and Catheter Treatment Trial; n = 1,000). Logistic regression was used to test for an interaction between subphenotype and treatment for mortality. We used stepwise modeling to generate a model for subphenotype identification in FACTT and validated its accuracy in the two cohorts in which we previously identified ARDS subphenotypes. Measurements and Main Results: We confirmed that a two-class (two-subphenotype) model best described the study population. Subphenotype 2 was again characterized by higher inflammatory biomarkers and hypotension. Fluid management strategy had significantly different effects on 90-day mortality in the two subphenotypes (P = 0.0039 for interaction); mortality in subphenotype 1 was 26% with fluid-liberal strategy versus 18% with fluid-conservative, whereas mortality in subphenotype 2 was 40% with fluid-liberal strategy versus 50% in fluid-conservative. A three-variable model of IL-8, bicarbonate, and tumor necrosis factor receptor-1 accurately classified the subphenotypes. Conclusions: This analysis confirms the presence of two ARDS subphenotypes that can be accurately identified with a limited number of variables and that responded differently to randomly assigned fluid management. These findings support the presence of ARDS subtypes that may require different treatment approaches.

1 September 2018 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
CCCarolyn S Calfee
Carolyn S Calfee
KDKevin L Delucchi
Kevin L Delucchi
PSPratik Sinha
Pratik Sinha
MMMichael A Matthay
Michael A Matthay
JHJonathan Hackett
Jonathan Hackett
GSGareth Sellors
Gareth Sellors

1 January 2015 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
JWJennifer G Wilson
Jennifer G Wilson
KLKathleen D Liu
Kathleen D Liu
HZHanjing Zhuo
Hanjing Zhuo
LCLizette Caballero
Lizette Caballero
MMMelanie McMillan
Melanie McMillan
MMMichael A Matthay
Michael A Matthay

1 June 2015 in Chest
Verified
Journal Article
Closed access
CCCarolyn S. Calfee
Carolyn S. Calfee
DJDavid R. Janz
David R. Janz
GBGordon R. Bernard
Gordon R. Bernard
AMAddison K. May
Addison K. May
KKKirsten N. Kangelaris
Kirsten N. Kangelaris
LWLorraine B. Ware
Lorraine B. Ware

20 May 2008 in Thorax
Verified
Journal Article
Open access
PDF file
CCC S Calfee
C S Calfee
LWL B Ware
L B Ware
MEM D Eisner
M D Eisner
PPP E Parsons
P E Parsons
BTB T Thompson
B T Thompson
TNThe Nhlbi Ards Network
The Nhlbi Ards Network
Objectives: To determine whether baseline plasma levels of the receptor for advanced glycation end products (RAGE), a novel marker of alveolar type I cell injury, are associated with the severity and outcomes of acute lung injury, and whether plasma RAGE levels are affected by lower tidal volume ventilation. Design, setting and participants: Measurement of plasma RAGE levels from 676 subjects enrolled in a large randomised controlled trial of lower tidal volume ventilation in acute lung injury. Measurements and main results: Higher baseline plasma RAGE was associated with increased severity of lung injury. In addition, higher baseline RAGE was associated with increased mortality (OR for death 1.38 (95% CI 1.13 to 1.68) per 1 log increment in RAGE; p = 0.002) and fewer ventilator free and organ failure free days in patients randomised to higher tidal volumes. These associations persisted in multivariable models that adjusted for age, gender, severity of illness and the presence of sepsis or trauma. Plasma RAGE was not associated with outcomes in the lower tidal volume group (p = 0.09 for interaction in unadjusted analysis). In both tidal volume groups, plasma RAGE levels declined over the first 3 days; however, the decline was 15% greater in the lower tidal volume group (p = 0.02; 95% CI 2.4% to 25.0%). Conclusions: Baseline plasma RAGE levels are strongly associated with clinical outcomes in patients with acute lung injury ventilated with higher tidal volumes. Lower tidal volume ventilation may be beneficial in part by decreasing injury to the alveolar epithelium.